A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer.
S KawakamiH TsumuraT SatohK TabataA SekiguchiT KainumaM NakanoM IwamuraHiromichi IshiyamaPublished in: Radiation oncology (London, England) (2022)
Our phase II study showed that SBRT delivering 36 Gy in 4 fractions was safe and effective with favorable QOL outcomes, although this regimen showed slightly more severe toxicities compared to current standards.
Keyphrases
- phase ii study
- locally advanced
- prostate cancer
- open label
- radiation therapy
- rectal cancer
- placebo controlled
- radical prostatectomy
- squamous cell carcinoma
- early stage
- radiation induced
- clinical trial
- early onset
- study protocol
- adipose tissue
- type diabetes
- metabolic syndrome
- drug induced
- double blind
- skeletal muscle
- insulin resistance